Oncology Brothers: Practice-Changing Cancer Discussions

2023 World Conference on Lung Cancer Highlights | Dr. Stephen Liu | Oncology Brothers #2023

In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Liu: - FLAURA2 - studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets - CHRYSALIS-2 - post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination with Lazertinib plus chemo - MARS2 - when compared surgery followed by chemo vs chemo alone, chemo alone had better outcomes in patients with resectable mesothelioma - EVOKE-02 - Sacituzumab approved bladder and breast cancer, was tested here along with Pembrolizumab in 1st line mNSCLC setting, with more data to come to confirm its arrival in this space #WCLC #IASLC #LungCancer #2023 #cancer #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

How to Treat Chronic Lymphocytic Leukemia (CLL) with Dr. Jeff Sharman

In discussion with Dr. Jeff Sharman, about how to treat CLL. Chronic lymphocytic leukemia course has changed since we have started using BTK inhibitors. Dr. Sharman, director of hematology research at US Oncology Network and Director of Research at Willamette Valley Cancer Institute, was the first to ever give this medication here in the US. We discuss important nuances of CLL management with him, when to proceed with observation vs. treatment, when treating what BTKi to utilize, important side effects one has to keep in mind, and much more.

Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin’s Lymphoma

Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin's Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg - Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).

Story of Hope by a Determined Lung Cancer Survivor - Jill Feldman

Discussing the story of hope and determination from the lung cancer survivor herself, Jill Feldman. Jill, talks about her lung cancer journey from limited stage to advanced stage with metastases, and how novel therapies have given her another chance of reliving her life, dreams and spending quality time with friends and family. Jill, has been an active patient advocate in the cancer space, and co-founder of EGFR Positive Lung Cancer Resisters Advocacy Group.

EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab

Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg - Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.

How to Treat MGUS and Smoldering Myeloma with Dr. S. Vincent Rajkumar

Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an algorithm with Dr. S. Vincent Rajkumar. We covered MGUS and smoldering myeloma in great detail, following with how these patients should be monitored and if any of these patients should be treated. Dr. S. Vincent Rajkumar is a world-renowned physician who specializes in plasma cell disorders - Professor of Medicine at the Mayo Clinic Comprehensive Cancer Center.

How to Treat Multiple Myeloma with Dr. Jens Hillengass

Discussing how to treat multiple myeloma using an algorithm with Dr. Jens Hillengass. We cover the first line, following that recurrence and refractory myeloma management in great detail. Dr. Jens Hillengass is the Chief of Myeloma, Professor of Oncology and Internal Medicine at the Roswell Park Comprehensive Cancer Center - University at Buffalo. 

Critical Updates in Kidney, Prostate, and Bladder Cancer from ASCO 2023 with Dr. Toni Choueiri

Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School - Dana-Farber Cancer Institute.
Covering four important studies:
- TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations
- CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma
- CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma
- THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration

GI Cancer ASCO 2023 Highlights with Dr. Muhammad Shaalan Beg

Discussing GI (Gastrointestinal) Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Muhammad Shaalan Beg, Co-Leader Gastrointestinal Oncology, Adjunct Associate Professor of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center. Covering three important studies:
- PROSPECT: ph III trial of neoad chemoRT vs neoadj FOLFOX chemo with selective use of chemoRT, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)
- NORPACT-1: Short-course neoadj FOLFIRINOX vs upfront surgery for resectable pancreatic head cancer
- NAPOLI 3: ph III trial in mets pancreatic ductal adenocarcinoma pts, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) vs nab-paclitaxel + gemcitabine
- IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) from the phase III IMbrave050 trial of adj atezo + bev vs active surveillance in pts with HCC

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:
- ADAURA trial update with increased OS with adjuvant Osimertinib
- KEYNOTE 789 - Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant
- KEYNOTE 671 - Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC